# A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.

> **NCT04661917** · PHASE2 · WITHDRAWN · sponsor: **Bayer**

## Conditions studied

- Chronic Kidney Disease
- Diabetic Kidney Disease

## Interventions

- **DRUG:** BAY2327949
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04661917
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-05-31
- **Primary completion:** 2022-04-25
- **Final completion:** 2022-05-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn due to company decision
- **Last updated:** 2021-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04661917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04661917, "A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04661917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*